fr   en
Clinical Studies
Phase :    
Announcement :   
Select a Pharma :
Select a product :
Select a disease :
Choose date:
[<<]      «      1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11      »      [57]
Date Phase Anouncement Biotech Pharma Product Disease Country Other
2010-06-05 II Result immatics (Germany)   IMA910 (peptide based therapeutic vaccine consisting of 13 synthetic tumor-associated peptides representing tumor antigens specific for colorectal cancer) advanced renal cell carcinoma   See details
2010-06-02 II Launch Nabriva Therapeutics (Austria)   BC-3781 (pleuromutilin antibiotic) acute bacterial skin and skin structure infections USA See details
2010-05-31 Other Launch Genfit (France)   new biomarkers of Bêta-cell dysfunction analysis of the association between glycemic or ponderal status and tissue gene expression pre-diabetes and early stages of diabetes   See details
2010-05-28 III Result   AstraZeneca (UK) Recentin® (cediranib) metastatic colorectal cancer   See details
2010-05-27 III Launch     Lu AA21004 (5-HT3, 5-HT7 and 5-HT1B receptor antagonist, 5 HT1A receptor agonist and 5-HT transporter inhibitor major depression Europe, USA, Canada See details
2010-05-21 II Result Cytos Biotechnology (Switzerland)   CYT003-QbG10 allergic asthma   See details
2010-05-20 I Launch Galapagos (Belgium)   GLPG0492 (orally available small molecule that Galapagos has developed in its Selective Androgen Receptor Modulator (SARM) program). The product is the fifth candidate drug to enter the clinic for Galapagos. cachexia Belgium See details
2010-05-19 III Launch Movetis (Belgium)   prucalopride opioid-induced constipation (OIC) Europe See details
2010-05-19 I-II Result Vaxon Biotech (France)   Vx-001 cancer including non small cell lung cancer   See details
2010-05-19 I-II Launch Apitope (Belgium-UK)   ATX-MS-1467 (peptide-based therapeutic derived from Apitope’s proprietary technology platform) The product is developed with Merck Serono (See http://www.biopharmaceutiques.com/fr/tables/agreements_481.html). multiple sclerosis UK See details
2010-05-19 I Launch Evotec (Germany) Boehringer Ingelheim (Germany) undisclosed compound This compound was discovered and optimised within the 2004 multi-year, multi-target drug discovery collaboration between Evotec and Boehringer Ingelheim. neuropathic pain   See details
2010-05-18 III Result PregLem (Switzerland)   Esmya® (ulipristal acetate) symptomatic uterine fibroids (myoma).   See details
2010-05-17 Other Launch BioInvent International (Sweden) Thrombogenics (Belgium) Roche (Switzerland) TB-403 ((RG7334 - humanized monoclonal antibody targeting the angiogenic factor PlGF (placental growth factor) metastatic, treatment-refractory, colorectal and ovarian cancers Europe See details
2010-05-11 I Launch Crucell (The Netherlands)   Ad35-CS (AdVac®-based malaria vaccine vector) Crucell is developing its malaria vaccine vector in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), the Centre National de Recherche et de Formation sur le Paludisme (CNRFP) in Burkina Faso, and the Noguchi Memorial Institute for Medical Research at the University of Ghana. malaria Burkina Faso See details
2010-05-10 III Launch Vectura (UK) Novartis (Switzerland) QVA149 once-daily, dry powder bronchodilator for inhalation combining a fixed dose of the once-daily beta2–agonist QAB149 (indacaterol) and the long-acting muscarinic antagonist NVA237 (glycopyrronium bromide) Vectura and Sosei concluded a global development and commercialisation agreement with Novartis in April 2005 for their collaborative product NVA237. Novartis is responsible for developing and commercialising NVA237 both as a monotherapy and in combination with QAB149 (indacaterol), its once-daily, long-acting beta2-agonist, as QVA149. The product entered Phase III trials in June 2009 which triggered an earlier milestone payment of $7.5m to each company. chronic obstructive pulmonary disease (COPD) USA, Europe and other territories See details
[<<]      «      1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11      »      [57]